Genetic testing instrument maker Affymetrix Inc. said Wednesday that Frank Witney will replace outgoing President and CEO Kevin King.
King will resign to pursue other interests, effective June 30, the company said.
Witney has worked in the life sciences industry for over 30 years, most recently as CEO of Dionex Corp., which completed its $2.1 billion sale to Thermo Fisher Scientific Inc. last month.
Before joining Dionex in April 2009, Witney served as executive vice president and chief commercial officer of Affymetrix, following Affymetrix's acquisition of Panomics. He has also served as an executive at Bio-Rad.
Shares of Affymetrix, based in Santa Clara, Calif., rose 17 cents, or 2.8 percent, to $6.26 in morning trading.